Falk Gastro Info 8 i 9/2024

Ho FF et al, Gut. 2024;73(6):922–931

Lifestyle behavior and irritable bowel syndrome: Adhering to a higher number of healthy lifestyle behaviors (never smoking, optimal sleep, vigorous physical activity, high dietary quality and moderate alcohol intake) was significantly associated with a lower incidence of irritable bowel syndrome in a large British prospective and population-based cohort study.

Janssen HLA et al, Lancet Gastroenterol Hepatol. 2024;9(8):718–33

Phase II study analyses the safety and effectiveness of tenofovir alafenamide (TAF) in patients with chronic hepatitis B and renal or hepatic impairment: This study included patients who were treated with a nucleos(t)ide analogue for chronic hepatitis B and who also had moderate to end-stage renal impairment or decompensated liver disease. The analysis over 2 years shows that TAF is virologically effective and at the same time has a favorable side effect profile in terms of kidney function and bone density parameters. These data therefore underline that switching therapy to TAF can be effective and safe even in cases of impaired kidney or liver function.

Engström A et al, Hepatology. 2024;79(6):1401–11

Cohort study from Scandinavia demonstrates beneficial effect of glucagon-like peptide-1 (GLP-1) receptor agonists on the progression of metabolic liver diseases: This large cohort study examined the development of liver cirrhosis or hepatic decompensation as well as the development of hepatocellular carcinoma in patients with diabetes in whom a therapy with either a GLP-1 receptor agonist (n = 91,479) or a dipeptidyl peptidase-4 inhibitor (n = 244,004) was initiated. In the comparative analysis, the liver-relevant end points occurred significantly less frequently in patients who were treated with a GLP-1 receptor agonist. This study therefore supports the assumption that GLP-1 receptor agonists appear to have a beneficial effect on metabolic liver diseases.

Cook D et al, N Engl J Med. 2024;391(1):9-20

Stress ulcer prophylaxes during invasive mechanical ventilation: Pantoprazole resulted in a significantly lower risk of clinically important gastrointestinal bleeding as compared to placebo in a large, randomized trial involving more than 4800 patients. However, mortality as well as ventilator-associated pneumonia or infections with Clostridoides difficile were not altered.